BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9365014)

  • 21. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
    Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
    Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
    Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat.
    Cumming P; Ase A; Diksic M; Harrison J; Jolly D; Kuwabara H; Laliberté C; Gjedde A
    Biochem Pharmacol; 1995 Sep; 50(7):943-6. PubMed ID: 7575677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA.
    Endres CJ; DeJesus OT; Uno H; Doudet DJ; Nickles JR; Holden JE
    Front Biosci; 2004 Jan; 9():505-12. PubMed ID: 14766386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
    Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
    Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
    Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
    J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA.
    Yee RE; Cheng DW; Huang SC; Namavari M; Satyamurthy N; Barrio JR
    Biochem Pharmacol; 2001 Nov; 62(10):1409-15. PubMed ID: 11709201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
    Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.
    Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Zanzi I; Mandel F; Spetsieris P; Eidelberg D
    J Nucl Med; 1994 Jun; 35(6):955-63. PubMed ID: 8195882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents.
    Creveling CR; Kirk KL
    Biochem Biophys Res Commun; 1985 Aug; 130(3):1123-31. PubMed ID: 3927916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates.
    Chan GL; Doudet DJ; Dobko T; Hewitt KA; Schofield P; Pate BD; Ruth TJ
    Life Sci; 1995; 56(21):1759-66. PubMed ID: 7739350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Striatal 18F-dopa uptake: absence of an aging effect.
    Eidelberg D; Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Margouleff D; Moeller JR; Patlak CS; Fahn S
    J Cereb Blood Flow Metab; 1993 Sep; 13(5):881-8. PubMed ID: 8360294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influx of neutral amino acids into the porcine brain during development: a positron emission tomography study.
    Brust P; Vorwieger G; Walter B; Füchtner F; Stark H; Kuwabara H; Herzau M; Opfermann T; Steinbach J; Ganapathy V; Bauer R
    Brain Res Dev Brain Res; 2004 Sep; 152(2):241-53. PubMed ID: 15351512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
    J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
    Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
    Doudet DJ; Chan GL; Holden JE; Morrison KS; Wyatt RJ; Ruth TJ
    Neuropharmacology; 1997 Mar; 36(3):363-71. PubMed ID: 9175615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations.
    Yee RE; Huang SC; Stout DB; Irwin I; Shoghi-Jadid K; Togaski DM; DeLanney LE; Langston JW; Satyamurthy N; Farahani KF; Phelps ME; Barrio JR
    J Neurochem; 2000 Mar; 74(3):1147-57. PubMed ID: 10693947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
    Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
    Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.